Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
piggyBac CD19 CAR T cells in relapsed/refractory CD19-positive B-ALL
jRCT2043240206Phase 2Recruiting
- Start
- Apr 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UCD19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL). Primary endpoints: Incidence of dose-limiting toxicity (DLT) and Overall remission rate (ORR). Started Apr 2025; status: recruiting.
02
Drugs
UCD19 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on jRCT2043240206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043240206.